An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from the University of Toronto and Manchester University.
Their work, published today in the journal Medical Mycology, has also re-estimated the total number of asthmatics worldwide – to reveal a staggering 193 million sufferers. Twenty-four million asthma sufferers live in the United States, 20 million each in India and China, and seven million in the United Kingdom.
Clinical studies have shown that oral antifungal drugs significantly improve symptoms and asthma control in asthmatics with ABPA, treatment endorsed by the Cochrane Collaboration. This is the first time that a global estimate of ABPA numbers has been made.
In national league tables of asthma rates in adults, only Australia and Sweden have a higher prevalence than the UK. In global league tables of ABPA occurrence, New Zealand tops the list with a 3.5% rate in new patients attending chest clinics at hospitals. The rates were 2.6% in Cape Town, 2.3% in Saudi Arabia, 2.5% in China and 0.7% in an older study from Ireland. No population-based studies have been done.
In addition to standard asthma therapy, the antifungal therapy used is itraconazole – now a generic, inexpensive antifungal – with a response rate of 60%. The researchers also found that antifungal therapy also benefits patients with severe asthma sensitized to fungi, called SAFS.
Alternatives include voriconazole and posaconazole, which have 75-80% response rates. In a recent assessment of voriconazole and posaconazole for both ABPA and SAFS, 75% of patients were able to stop taking oral corticosteroids, a major benefit, and 38% of patients had their asthma severity downgraded on antifungal therapy.
Professor David Denning, professor of medicine and medical mycology at the University of Manchester and Director of the University Hospital of South Manchester’s National Aspergillosis Centre, led the study into the total number of asthmatics worldwide. He said the study results implied that asthma admissions and deaths could be avoided with more extensive use of antifungal therapy.
“We were surprised by the number of patients with ABPA, and by the lack of community based studies done,” he said. “Our National Aspergillosis Centre treats hundreds of these patients each year, generally with major improvement, and so a conscious program to seek out ABPA from all asthmatics is required.”
The Latest Bing News on:
- Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofim | Morningstaron August 4, 2022 at 2:25 am
Get 7 Days Free Sign In Sign In Topics ...
- F2G to push anti-fungal agent with new $70M fundingon August 4, 2022 at 1:01 am
F2G, a clinical-stage biopharma company focused on treating life-threatening rare fungal infections, has announced $70M of financing.
- Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofimon August 4, 2022 at 12:34 am
The new funding will enable F2G to advance development and preparations for the commercialization in the US of olorofim, a novel oral antifungal therapy to treat invasive aspergillosis (IA ...
- Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofimon August 4, 2022 at 12:02 am
Forbion, a leading European life sciences venture capital firm, today announces the $70 million financing of F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and ...
- F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofimon August 4, 2022 at 12:00 am
F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections with a high unmet medical need, today ...
- High prevalence of fungal secondary infections among COVID-19 patientson August 1, 2022 at 5:00 pm
Study: Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis. Image Credit: Kateryna Kon / Shutterstock.com Some commonly ...
The Latest Google Headlines on:
The Latest Bing News on:
- Sidra Medicine, QRDI Council to develop device to help treat asthmaon August 7, 2022 at 10:44 pm
Sidra Medicine, a specialist women’s and children’s hospital in Qatar, and the QRDI Council will use the QOI platform to develop a device to detect the severity of asthma attacks in children and help ...
- Asthma-Related Emergency Department Visits Can Indicate Poor Housing Conditionson August 7, 2022 at 6:30 am
Emergency department (ED) asthma visits can be an indicator of poor housing conditions, according to results of a study done in New Haven, Connecticut.
- My daughter had an allergy-induced asthma attack when we were visiting London. Our visit to the ER was friendly and incredibly efficient.on August 6, 2022 at 5:30 am
The author says her visit to the ER in London was patient-friendly and made her feel heard and supported. Her daughter even got a snack.
- Obesity, Physical Inactivity Linked With Higher Risk for Activity Limits in Asthmaon August 5, 2022 at 10:39 am
Patients with asthma and all types of obesity, or with all types of obesity and physical inactivity, have an increased risk for limited activity of daily living, according to the results of a recent ...
- Position Paper: Alpine Altitude Climate Treatment May Benefit Patients With Severe Asthmaon August 5, 2022 at 6:59 am
Patients with severe and uncontrolled asthma may benefit from alpine air, the European Academy of Allergy and Clinical Immunology reports.
- Is It Safe To Use A Heating Pad When You Have Asthma?on August 5, 2022 at 12:48 am
Finding relief during an asthma attack can be challenging, especially during spring or winter. Heating pads may relieve the painful symptoms of asthma.
- Climate change's aggravating impact on asthma suffererson August 4, 2022 at 9:06 pm
More than 50 million Americans suffer from allergies. It's the sixth leading chronic illness, and one in 13 people are affected. And in recent years, it seems like it's getting worse.
- Man almost died after heart stopped twice during first asthma attack he ever hadon August 3, 2022 at 9:14 am
After nearly losing his life, husband and dad Jamie Bell, 36, believes more education is needed on the condition. From mild to severe, here are the symptoms of asthma and what to do about it.
- Finding the lowest effective dose of asthma preventer medicineon August 2, 2022 at 9:31 pm
Seven out of ten Australians with asthma aged over 12 years may be prescribed too much preventer medicine. In Australian Prescriber Prof Helen Reddel and coauthors from the Woolcock Institute of ...
- What To Expect When You Go To The Hospital For A Severe Asthma Attackon August 2, 2022 at 4:48 pm
If you or a loved one has asthma, you understand how frightening asthma attacks can be. Here's what to expect if you're hospitalized for asthma treatment.